RACC Sets Nov 24 Vote on Oak Hill Bio Merger; $55M PIPE and $75M Backstop in Place
RACC is trading near its 52-week low of $9.62 (5.5% above the low) on light trading volume (0.2× avg).
Summary
RACC's amended S-4 sets the November 24, 2026 shareholder vote on its merger with Oak Hill Bio, with a $55M PIPE at $10.00, a $75M RA Capital backstop, and redemptions at about $10.03 per share due November 20.
Key Events · M&A and Partnerships · RACC
-
Merger Vote Set for November 24
RACC shareholders of record on October 13, 2026 will vote on the Oak Hill Bio business combination, the Domestication to Delaware and related proposals at an extraordinary general meeting on November 24, 2026.
-
Deal Priced at $160M Plus $45M SAFE
Closing consideration equals the $160,000,000 Base Equity Value plus the $45,000,000 Oak Hill Bio SAFE Amount, divided by $10.00 per share; Oak Hill Bio holders receive 14,080,000 shares, or 42.4% of the 33,178,529 shares outstanding post-closing.
-
$55M PIPE and $75M Backstop Fund the Deal
PIPE investors buy 5,500,000 shares at $10.00 for $55,000,000, and RA Capital Healthcare Fund backstops up to 7,500,000 shares ($75,000,000), so total sources of $203.0M leave $188.5M of cash on the balance sheet after $14.3M of transaction expenses.
-
Redemptions Capped at ~$10.03 per Share
Public holders must tender by 5:00 p.m. ET on November 20, 2026; based on the $75,238,468 trust balance at June 30, 2026 the redemption price is about $10.03 per share, and no holder or group may redeem more than 15% of the public shares.
Analysis · RACC · Life Sciences
This Amendment No. 2 to the S-4 is the filing that finally puts the Oak Hill Bio merger on the calendar: shareholders vote November 24, 2026, with a record date of October 13 and a redemption deadline of November 20 at roughly $10.03 per share. The deal math is unchanged from the original S-4 — $160M base equity value plus the $45M SAFE, a $55M PIPE at $10.00, and a $75M backstop from RA Capital that makes proceeds largely insensitive to redemptions. For holders, dilution is the key issue: Oak Hill Bio holders end up with 42.4% of the combined company, and the Sponsor/backstop affiliate's stake swings from 18.2% to 40.8% as public holders redeem, while public holders go from 22.6% to zero. Because the Sponsor paid about $0.02 per founder share versus $10.00 for public and PIPE investors, it profits even if the stock falls well below $10 — a structural conflict the filing flags explicitly. With a going-concern warning and material weakness already on the record from the August 10-Q, approval and Nasdaq listing are the gating items; a failure to clear either sends RACC toward liquidation by May 21, 2028.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RACC was trading at $10.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.4M. The 52-week trading range was $9.62 to $33.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.